Belgian atopic dermatitis guidelines.

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice.

[How I explore … an hypersensitivity to iodinated contrast media].

Immediate or delayed hypersensitivity reactions to iodinated contrast media (ICM) occur in 0.5-3 % of patients receiving radiological examinations using the last generation ICM. Although the majority of the reactions are mild to moderate, severe and potentially lethal reactions may occasionally be observed.

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).

Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.

Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges.

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased.

The dramatic increase in the rate of methylisothiazolinone contact allergy in Belgium: a multicentre study.

Background: The rate of contact allergy and allergic contact dermatitis caused by methylisothiazolinone (MI) is dramatically increasing throughout Europe.

Objectives: To report on methylchloroisothiazolinone (MCI)/MI and MI allergy in Belgium.

Patients And Methods: Between January 2010 and December 2012, the medical charts of 6599 patients of the Belgian Contact and Environmental Dermatitis Group were retrospectively reviewed for MCI/MI and MI sensitization by use of a standardized questionnaire.